Clinical Trials Logo

Clinical Trial Summary

This randomized phase III trial is studying melphalan and dexamethasone to see how well they work with or without bortezomib in treating patients with previously untreated systemic amyloidosis. Drugs used in chemotherapy, such as melphalan and dexamethasone, work in different ways to stop the growth of plasma cells, either by killing the cells or by stopping them from dividing. Bortezomib may stop the growth of plasma cells by blocking some of the enzymes needed for cell growth. It is not yet known whether giving melphalan together with dexamethasone is more effective with or without bortezomib in treating systemic amyloidosis.


Clinical Trial Description

PRIMARY OBJECTIVES: I. To compare hematologic overall response (partial response [PR], very good PR, amyloid complete hematologic response [ACR], and stringent complete response [sCR]) after 3 courses of therapy in patients with previously untreated systemic light-chain amyloidosis treated with melphalan and dexamethasone with vs without bortezomib. SECONDARY OBJECTIVES: I. To evaluate the ACR rate after 3 courses of therapy and at completion of therapy. II. To evaluate organ response rates after 3 courses of therapy and at 6, 9, and 12 months. III. To evaluate treatment-related mortality. IV. To evaluate toxicity. V. To evaluate progression-free and overall survival. VI. To evaluate PR or better at completion of therapy. VII. To evaluate time to hematologic and organ response. VIII. To evaluate the duration of hematologic and organ response. IX. To assess quality of life (QOL) at baseline, at 3, 6, and 9 months during the therapy, at completion of therapy, and 3 and 6 months after therapy. TERTIARY OBJECTIVES: I. To determine the prognostic impact of t(11;14) translocation and cyclin D1 overexpression on response and overall survival. II. (Correlative) To compare sCR rates and to determine the impact of sCR on the outcomes. III. (Correlative) To perform a descriptive analysis of amyloid typing and proteomic composition of amyloid tissues. OUTLINE: This is a multicenter study. Patients are stratified according to amyloid cardiac stage (stage I/II vs. better risk stage III) and are randomized to 1 of 2 treatment arms. ARM A (Mel-Dex): Patients receive melphalan 0.22 mg/kg orally (PO) and dexamethasone 40 mg PO on days 1-4 every 4 weeks. Treatment repeats every 4 weeks for up to 9 courses in the absence of disease progression or unacceptable toxicity. ARM B (B-Mel-Dex): Patients receive melphalan 0.22 mg/kg PO and dexamethasone 40 mg PO on days 1-4 and bortezomib 1.3 mg/m2 intravenously (IV) on days 1, 4, 8, and 11 every 4 weeks. Treatment repeats every 4 weeks for 2 cycles. Patients then receive melphalan PO and dexamethasone PO on days 1-4 and bortezomib IV on days 1, 8, 15, and 22 every 5 weeks. Treatment repeats every 5 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Blood, urine, bone marrow, and fat samples may be collected periodically for laboratory analysis. Health-related quality of life is assessed periodically before, during, and after therapy. After completion of study treatment, patients are followed up periodically for 5 years. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01078454
Study type Interventional
Source National Cancer Institute (NCI)
Contact
Status Completed
Phase Phase 3
Start date November 2010
Completion date November 27, 2012

See also
  Status Clinical Trial Phase
Completed NCT00520767 - Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition Disease Phase 2
Completed NCT01194791 - Lendexal in Patients With Primary Systemic Amyloidosis (AL) Newly Diagnosed Phase 2
Completed NCT02207556 - Doxycycline to Upgrade Organ Response in Light Chain (AL) Amyloidosis Trial Phase 2
Completed NCT00112593 - Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer N/A
Completed NCT00006251 - Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer Phase 1/Phase 2
Terminated NCT01728259 - First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD Phase 1
Completed NCT01072773 - Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Light Chain Amyloidosis Phase 2
Active, not recruiting NCT03499808 - S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis Phase 2
Completed NCT00536601 - High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors N/A
Completed NCT00224393 - Phase II Trial of Enbrel in Patients With Primary Systemic Amyloidosis Phase 2
Completed NCT01199562 - Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant
Terminated NCT00030381 - Iododoxorubicin in Treating Patients With Primary Systemic Amyloidosis Phase 1
Completed NCT00014235 - Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies N/A
Completed NCT00890747 - Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy Phase 1
Completed NCT00025415 - Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction Phase 1
Completed NCT01849783 - Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma Phase 2
Completed NCT01053494 - Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer N/A